@FiercePharma: With tough Japanese enforcers eyeing its Blopress marketing, Takeda chief admits missteps. Story | Follow @FiercePharma
@TracyStaton: This year's version of FiercePharma's most popular special report: The top 10 pharma companies by 2013 revenue. Report | Follow @TracyStaton
@EricPFierce: WSJ says Pfizer angling for OTC Lipitor. That will get generic drugmakers' notice. More | Follow @EricPFierce
@CarlyHFierce: Roche, by the way, was No. 3 when it comes to 2013 revenue - read more here and see the rest of the top 10. Report | Follow @CarlyHFierce
> Pfizer ($PFE) has been sued in federal court in West Virginia by four women who allege their type 2 diabetes is linked to taking Pfizer's cholesterol-lowering blockbuster Lipitor. Story
> Sagent Pharmaceuticals is recalling two lots of Zoledronic Acid Injection after investigating a complaint of leaking bags. Release
> Top NuPathe executives could see their $8 million in stock, options, warrants and units nearly double as a result of the company's buyout by Teva Pharmaceutical Industries. Story
> A new federal study found that some U.S. doctors use three times as many antibiotics as their peers for treating similar conditions, contributing to the development of superbugs. Story (sub. req.)
> Novo Nordisk ($NVO) announced study results during the Diabetes UK conference suggesting that psychological support, along with education and self-management, should be a priority for diabetes care in the UK. Story
@FierceMedDev: 1,000 people (and rising) are gearing up to sue Medtronic over its Infuse bone growth implant. More | Follow @FierceMedDev
@MarkHFierce: Uh-oh for Thoratec. Some heart pump safety troubles. Story via WSJ (sub. req.) | Follow @MarkHFierce
@GalenMoore: Upheld: Former Spectranetics CEO's conviction for lying to the feds over device smuggling allegations. Story | Follow @GalenMoore
@EmilyWFierce: GE Healthcare slapped with FDA's most serious recall for some of its infant resuscitation products. More | Follow @EmilyWFierce
> The FDA will mull Navidea's latest pitch to widen the use of its injectable cancer imaging agent. Brief
> Word of a $16M Coloplast vaginal-mesh settlement spurs global resolution talk. Article
Biotech News
@FierceBiotech: FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin. More | Follow @FierceBiotech
@JohnCFierce: Analysts applaud as Bristol-Myers preps a PhIII study for PD-1 cancer combo. Editor's Corner | Follow @JohnCFierce
@DamianFierce: FDA rejects Lilly and Boehringer's diabetes drug (SGLT2-blocker) over manufacturing issue. Release | Follow @DamianFierce
@EmilyMFierce: This week's issue of FierceBiotech Research is out: Read | Follow @EmilyMFierce
> Biogen Idec buys into Eisai's BACE camp on Alzheimer's as drug race heats up. News
> Xoma drug fails to beat out a placebo in PhII osteoarthritis study. Article
Drug Delivery News
> AstraZeneca looks to pen injector approval to turn Bydureon diabetes sales around. Story
> Teva, Alexza launch inhaled schizophrenia, bipolar treatment in the U.S. News
> Neos collects $15.5 from private investors to bring ADHD extended-release option to market. News
> Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job. Article
> New manufacturing technique offers tailored delivery nanoparticles made of iron, silver and silicon. Story
> Tattoo-mediated delivery offers possible treatment for sandfly-borne skin disease. Brief
Diagnostics News
> J. Craig Venter raises $70M for a gene-sequencing and therapeutic startup. News
> Sequenom counts on prenatal test growth to reverse its fortunes. Story
> Qiagen launches its HPV test in India with low-resource areas in mind. Article
> Biodesix's CE mark triggers wider access for its personalized lung cancer treatment Dx. Story
> NEJM study scores Illumina prenatal test high for reducing false positives. Research
> CardioDx confronts tough reimbursement climate by touting cost-effective CAD test. Brief
Pharma Marketing News
> It's trial by fire for Zogenix, as painkiller Zohydro's launch meets public furor. Story
> Sanofi expands Kynamro marketing team to spark up sales. News
> Critics may play whack-a-mole on pharma's doctor-speakers, but the species lives on. Article
> Can Teva persuade payers that pricey long-acting Copaxone beats cheap generics? Article
> Aiming for big growth in top 5 meds, Bayer will stake an extra $600M on marketing, R&D. Story
> With tough Japanese enforcers eyeing its Blopress marketing, Takeda chief admits missteps. Brief
And Finally... Merck ($MRK), which is evaluating the future of its animal health unit, reports that a study found its Activyl is a more effective flea treatment for pets than competitor Frontline Plus from Merial Ltd. of Duluth, GA. Story